Scientists hunt for clues to predict who benefits from targeted cancer drug

NCT ID NCT04257162

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 31 times

Summary

This study looks at tumor and blood samples from 180 people with metastatic cancer who have been treated with the drug trastuzumab deruxtecan (T-DXd). The goal is to find a specific genetic marker (ERBB2 mRNA level) that can predict how well a patient will respond to the drug. No new treatments are given; the study only collects and analyzes existing samples to improve future treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • H.Univ. Arnau de Vilanova de Lleida

    Lleida, Lleida, Spain

  • Hospital Clínic de Barcelona

    Barcelona, Barcelona, 08036, Spain

  • Hospital La Paz

    Madrid, Madrid, 28046, Spain

  • Hospital Universitari Vall d' Hebron

    Barcelona, Spain

  • Hospital Universitario 12 de octubre

    Madrid, Spain

  • Hospital Universitario Virgen de la Arrixaca

    Murcia, 30120, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitario de Canarias

    Santa Cruz de Tenerife, Canary Islands, 38320, Spain

  • Hospital Universitario de Jerez

    Jerez de la Frontera, Cadiz, 11407, Spain

  • Hospital Virgen de Macarena

    Seville, Sevilla, Spain

  • Hospital Virgen de la Victoria

    Málaga, Spain

  • Hospital del Mar

    Barcelona, Barcelona, 08003, Spain

  • ICO Badalona

    Badalona, Barcelona, Spain

  • ICO Hospitalet

    Barcelona, Spain

  • Instituto Valenciano de Oncología (IVO)

    Valencia, Valencia, 46009, Spain

Conditions

Explore the condition pages connected to this study.